Trials / Active Not Recruiting
Active Not RecruitingNCT06934109
Narrative Exposure Therapy for Adults With an Intellectual Disability
Acceptability and Feasibility of an Adapted Narrative Exposure Therapy (NET) Protocol for Individuals With an Intellectual Disability
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- University of Nottingham · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this naturalistic single case series design is to investigate if an adapted Narrative Exposure Therapy protocol can be effective, is feasible, and acceptable for adults with a mile learning disability. Participants will be complete three baseline sessions before taking part in Narrative Exposure Therapy using a manual that has been adapted for people with a learning disability. Trauma symptoms will be measured weekly using the Impact of Events scale adapted for intellectual disabilities. The person's carer will also complete an informant scale related to these symptoms (LANTS-IV). The client will also complete the CORE-LD at pre, and post therapy. Six weeks after the end of the intervention, the client and their carer will be invited to a feedback session to talk about how they found the intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Narrative Exposure Therapy (NET) | NET is a psychological talking therapy that has been designed for people who have experienced multiple and prolonged traumatic experiences. It is typically 12-sessions, involving first a psychoeducation session, then laying a lifeline where stones are lain to represent traumatic events, and flowers positive life events. The following sessions the person is asked to talk through their life, going into detail on the traumatic memories that they have experienced. |
Timeline
- Start date
- 2024-12-03
- Primary completion
- 2025-09-01
- Completion
- 2026-02-01
- First posted
- 2025-04-18
- Last updated
- 2025-04-18
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT06934109. Inclusion in this directory is not an endorsement.